选择性雌激素受体调节器在激素替代疗法中的作用的新进展:一个范式转变
Gunjan Motlani1, Vidhi Motlani1, Neema Acharya2
1Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Cureus
|December 21, 2023
概括
选择性雌激素受体调节剂 (SERM) 为骨质疏松症和乳腺癌等疾病提供有针对性的治疗方法. 新的SERM显示出增强疗效的希望,尽管需要考虑潜在的不良影响.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 雌激素通过雌激素受体 (ERα和ERβ) 调节生理过程.
- 选择性雌激素受体调节剂 (SERM) 作为特定组织的激动剂或对抗剂.
- SERM用于骨质疏松症,乳腺癌和更年期症状.
研究的目的:
- 审查SERM的开发和发现.
- 详细介绍开发后期阶段的新型SERM分子.
- 讨论SERMs的治疗应用和不良影响.
主要方法:
- 关于SERM开发和临床应用的文献综述.
- 对第一代和第二代SERM (塔莫西芬,拉洛西芬) 的分析.
- 新兴SERM的描述:奥斯佩米芬,拉索福西芬,巴兹多西芬,阿尔佐西芬.
主要成果:
- 第一代SERM如Tamoxifen用于ER阳性乳腺癌.
- 拉洛西芬对绝经后的骨质疏松症和脊椎骨折的预防是有效的.
- 新的SERM证明了骨质疏松症治疗和预防的功效增加.
结论:
- 在管理与雌激素相关的疾病方面,SERM代表了显著的治疗进步.
- 新的SERM提供了更好的疗效,但需要持续的安全评估.
- 副作用,包括血栓塞栓性疾病和Tamoxifen的潜在子宫癌风险,需要小心选择患者.
相关概念视频
Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
Menopause
169
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
169
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Target Cell Response to Hormones
3.1K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
3.1K
Hormonal Regulation of the Menstrual Cycle
396
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
396
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
170
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170


